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Abstract: Inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease (CD),
are chronic debilitating disorders of unknown etiology. Over 200 genetic risk loci are associated with
IBD, highlighting a key role for immunological and epithelial barrier functions. Environmental factors
account for the growing incidence of IBD, and microbiota are considered as an important contributor.
Microbiota dysbiosis can lead to a loss of tolerogenic immune effects and initiate or exacerbate
inflammation. We aimed to study colonic mucosal microbiota and the expression of selected host
genes in pediatric UC. We used high-throughput 16S rDNA sequencing to profile microbiota in
colonic biopsies of pediatric UC patients (n = 26) and non-IBD controls (n = 27). The expression of
13 genes, including five for antimicrobial peptides, in parallel biopsies was assessed with qRT-PCR.
The composition of microbiota between UC and non-IBD differed significantly (PCoA, p = 0.001).
UC children had a decrease in Bacteroidetes and an increase in several family-level taxa including
Peptostreptococcaceae and Enterobacteriaceae, which correlated negatively with the expression of
antimicrobial peptides REG3G and DEFB1, respectively. Enterobacteriaceae correlated positively with
the expression siderophore binding protein LCN2 and Betaproteobacteria negatively with DEFB4A
expression. The results indicate that reciprocal interaction of epithelial microbiota and defense
mechanisms play a role in UC.
Keywords: inflammatory bowel disease; ulcerative colitis; microbiota; gene expression; host-microbe
cross-talk
1. Introduction
Inflammatory bowel diseases (IBD) affect up to seven million people globally and three million
in Europe and their incidence and prevalence are increasing [1,2]. The two main conditions of
IBD are ulcerative colitis (UC) and Crohn’s disease (CD). Epidemiological patterns suggest that
IBD will emerge as a major worldwide disease in the coming years [1,2]. The etiology of IBD is
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multifactorial and the course of pathogenesis is still largely unknown. Genome-wide association
studies (GWAS) have identified over 200 genetic loci as genetic risk factors for IBD [3] and more
recently, epigenetic alternations were described in the epithelium of IBD subjects [4]. The majority
of the IBD-associated genes code for immunological and epithelial barrier functions, which direct
the host´s response to environmental factors and consequently determine mucosal homeostasis [3].
Furthermore, both omics-based and targeted analysis of gene expression in the intestinal epithelium
have revealed IBD-associated alterations, which were independent from inflammation status [4,5].
Antimicrobial peptides (AMPs), including α- and β-defensins, C type lectins, cathelicidins and S100
proteins, are widely produced as a defense mechanism by intestinal epithelial cells to regulate and
maintain homeostasis between the microbiota and the host epithelium [6]. The expression of AMPs by
small intestinal Paneth cells, mainlyα-defensins, is altered in ileal CD resulting in reduced antimicrobial
activity, whereas in UC the colonic antimicrobial barrier, formed by a mucus layer retaining the AMPs,
is impaired despite the upregulated epithelial peptide production [6,7].
The growing incidence of IBD suggests that environmental factors that have changed during the
past decades, such as urbanization, hygienic conditions and microbial exposure, use of chemicals,
diet, smoking and the use of antibiotics and other medication, modify the disease risk of genetically
predisposed individuals [1,2,8]. Microbiota are a major dictator of the antigenic milieu in the intestine
and also have a regulatory effect on the host gene expression in the mucosa, and therefore can affect
immunological balance in the gut epithelium [9–12]. Both fecal and mucosal microbiota profiles of
IBD patients have been found to differ from those of healthy subjects, and microbiota with abnormal
composition, i.e., dysbiotic microbiota, are characteristic to the disease. The key findings include
reduced bacterial diversity, richness and stability [11,13–15], depletion of immune-regulatory species,
such as Akkermansia muciniphila [14] and Faecalibacterium prausnitzii and other butyrate-producing
bacteria [14,16], and increase in proinflammatory Proteobacteria, especially Enterobacteriaceae [10,17].
Overall, the depletion of core gut commensals, Bacteroidales and Clostridiales, is characteristic to IBD
and the disease-associated changes are more prominent in mucosa than feces [17,18]. Although it has
not been clarified whether microbiota perturbation is the cause or the result of inflammation, it seems
justified to consider the microbiota as one of the key players in IBD etiopathology. Furthermore, several
recent studies have indicated that microbiota profiles of treatment-naïve IBD patients are predictive for
the disease course and treatment responsiveness [18,19].
In Finland, the prevalence of IBD is high and the incidence of pediatric IBD increased up to 8% per
year in the early 2000s [20,21]. Registry-based cohort studies from both Finland and Sweden showed
that repeated use of antibiotics, especially cephalosporins, in childhood has been associated with an
increased risk of developing IBD [20,22], which may be due to the changes in the microbiota. Kolho and
colleagues studied the fecal microbiota in Finnish pediatric IBD patients and found reduced bacterial
richness and abundance of butyrate producers [21]. As mucosa-associated microbiota dysbiosis could
be more obvious and relevant for inflammation, we focused in this study on the mucosa-associated
microbiota of Finnish pediatric patients with ulcerative colitis (UC, n = 26) and non-IBD subjects
as (healthy) controls (non-IBD, n = 27). In addition, we studied the mucosal expression of selected
genes related to epithelial barrier function and coding for antimicrobial peptides or receptors for
bacterial recognition.
2. Results
2.1. Study Cohort and Effect of Sampling on the Microbiota
Clinical characteristics of the study groups are presented in Table 1. According to the Mayo
endoscopic subscore, 8 of the UC patients had inactive and 18 had active disease. The biopsies were
collected from different parts of the large intestine, i.e., cecum, ascending and descending colon,
and therefore we first investigated the possible effect of biopsy location on the microbiota composition.
The PCoA of all samples, both UC and non-IBD, indicated that biopsy location has a significant impact
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on the microbiota composition, although the subgroup analysis of UC and non-IBD did not separately
show the effect of location (Supplementary Figure S1). Further, the patient age had a significant
effect on the microbiota composition (Supplementary Figure S2). Based on these results, the sampling
location and age were included as confounders in all subsequent analysis.
Table 1. Patient demographics.
UC Active UC Inactive Control (HC)
Number of patients n = 18 n = 8 n = 27
Age (range) 13 (5–17) 14 (10–16) 8 (3–15)
Biopsy collected
ascending 8 3 2
cecum 4 4 17
descending 6 1 8
Mayo score
0 - 8 27
1 11 - -
2 5 - -
3 2 - -
Diagnosis or reason for diagnoctic colonoscopy
Pancolitis 16 7 -
Left-sided colitis 2 1 -
Diabetes mellitus - - 2
Diarrhea - - 7
Asthma - - 1
Abdominal pain - - 8
Hematochezia - - 9
Medication
None 7 0 24
5-ASA 11 8 -
Prednisolone 1 0 -
Azathioprine 4 3 -
Metotrexate - 1 -
Insulin - - 2
Budesonide - - 1
2.2. Mucosal Microbiota Associated with UC
In assessing the UC-associated microbiota, we first compared microbiota diversity and richness
between active, inactive disease and non-IBD, and found no significant difference between the groups
(Supplementary Figure S3).
Next, we compared the microbiota composition at bacterial phylum level. Non-IBD subjects
were found to harbor significantly less Firmicutes (Figure 1A, p = 0.006) than UC patients, as well as
more Bacteroidetes and less Proteobacteria as compared to UC, although the latter differences were
not statistically significant. Subsequent analysis with higher taxonomic resolution separated UC and
non-IBD in PCoA at bacterial family level (Figure 1B, p = 0.001) and disease activity accounted for 9%
of variation in the data (Figure 1C, p = 0.001).
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Figure 1. Colonic mucosal microbiota composition in ulcerative colitis (UC) subjects with active and
inactive disease compared to non-inflammatory bowel diseases (IBD) controls. (A) Bacterial phylum
level composition. Non-IBD controls had significantly less Firmicutes than UC patients (p = 0.006).
(B) PCoA on bacterial family level taxa and sample annotations to UC vs. non-IBD. (C) PCoA on
bacterial family-level taxa and sample annotations to UC active, UC inactive and non-IBD.
Concerning individual bacterial taxa at family level, Sutterellaceae, Veillonellaceae and unclassified
Erysipelotrichia were increased, and unclassified Bacteroidetes and Negativicutes decreased in
UC (Table 2). Further subgroup analysis revealed interesting patterns concerning increasing and
decreasing abundances of individual taxa from active to inactive UC and to non-IBD (Figure 2).
Most notably, unclassified Bacteroidales and Porhyromonadaceae (also belonging to the Bacteroidales
order) as well as unclassified Bacteroidia were decreased in UC as compared to non-IBD, whereas
Coriobacteriaceae, Streptococcaceae, Peptostreptococcaceae, Veillonellaceae, Enterobacteriaceae and
unclassified Gammaproteobacteria were increased in UC. Inactive UC differed from active disease
in having a decreased abundance of Streptococcaceae and Peptostreptococcaceae, and an increased
abundance of unclassified Saccharibacteria (formerly known as TM7 phylum), which was equally low
in abundance in active UC and non-IBD. Across all samples, Saccharibacteria correlated positively
with Micrococcaceae (r = 0.35, p = 0.01) and Ruminococcaceae (r = 0.28, p = 0.04).
Table 2. Family-level microbiota difference between ulcerative colitis (UC) patients and controls.
Taxon Fold Change in UC asCompared to HC p-Value q-Value
Uncultured Bacteroidetes 0.58 0.003 0.06
Uncultured Erysipelotrichia 7.27 0.021 0.17
Uncultured Negativicutes 0.61 0.005 0.06
Veillonellaceae 2.93 0.013 0.13
Sutterellaceae 4.35 2.96E-07 1.15E-05
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Figure 2. Family-level microbiota differences between active, inactive ulcerative colitis and non-IBD
controls. Microbiota abundance expressed as relative abundance. An asterisk indicates statistical
significance between active UC and non-IBD control.
2.3. Mucosal Gene exPression and Correlations with Microbial Taxa
The relative gene expression of 6 out of the 13 studied genes differed between UC subjects and
controls, and also between active and inactive disease (Table 3). The expression of interleukin 8
(IL-8), chemokine CXCL16, the calcium binding proteins S100A8 and S100A9 and lipocalin 2 (LCN2)
were significantly increased and the expression of antimicrobial peptide DEFB1 was significantly
decreased in UC patients when compared to non-IBD. The expression of the other studied genes for
antimicrobial peptides DEFB103B, DEFB4A, RETNLB and REG3G did not differ between the study
groups, although the last mentioned showed a tendency for decreased expression in UC (p = 0.076).
Further, the expression of trefoil factor 3 (TFF3), which is involved in the maintenance and repair of
intestinal mucosa, and the main colonic mucin MUC2 were at similar levels in both study groups.
Correlation analysis of the microbial and qRT-PCR data revealed correlations between the abundance of
family-level taxa and the expression of specific genes (Table 3). The abundance of Peptostreptococcaceae
and Enterobacteriaceae correlated negatively with the expression of antimicrobial peptides REG3g and
DEFB1, respectively. The abundance of Enterobacteriaceae correlated positively with the expression of
siderophore binding protein LCN2 and Betaproteobacteria correlated negatively with the expression
of DEFB4A. Sutterellaceae and Veillonellaceae had positive correlations with the expression of CXCL16
chemokine and its receptor CXCR6 as well as IL-8. The abundance of Lactobacillaceae correlated
negatively with the expression of CXCL16, S100A8 and S100A9.
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Table 3. Expression of selected genes and their associations with bacterial abundance.
Fold Change in Gene Expression Associations between Gene-Expression andMicrobiota
Gene Expression UC/HC UC Active/ UC Inactive Negative Positive
CXCL16 1.31 * 1.56 * Lactobacillaceae Veillonellaceae
CXCR6 ns. ns. - Sutterellaceae,Veillonellaceae
DEFB1 0.76 * 0.34 *** Enterobacteriaceae -
DEFB103B ns. ns. - -
DEFB4A ns. ns. UnculturedBetaproteobacteria -
IL8 68.19 *** 38.36 *** - Sutterellaceae,Veillonellaceae
LCN2 6.32 ** 7.59 ** - Enterobacteriaceae
MUC2 ns. ns. - Desulfovibrionaceae
REGIIIg ns. ns. Peptostreptococcaceae -
RETNLB ns. ns. - -
S100A8 18.78 ** 29.30 * Lactobacillaceae Actinomycetaceae
S100A9 8.58 * 17.12 ** Lactobacillaceae Actinomycetaceae
TFF3 ns. ns. - -
* p < 0.05, ** p < 0.001, *** p < 0.0001.
3. Discussion
Previous studies have suggested that both microbiota and impaired function of the intestinal
epithelium contribute to UC pathogenesis. Here, we carried out high-throughput sequencing of the
microbiota and applied a targeted host gene expression analysis to study mucosal microbiota–host
interactions in Finnish pediatric UC patients and controls. The main limitation of our study is that the
cohort size is relatively small and hence some of the results, particularly those showing associations
between microbial abundance with mucosal gene expressions, should be considered as preliminary,
and confirmed in a larger group of study subjects. Moreover, there was variation in the subjects’ age
and biopsy location, which was taken into account in the microbiota analyses. Unfortunately, we did
not gather long-term information on the history of antibiotic usage before the sampling, and it was not
possible to assess the impact of overall antibiotic use on microbiota in this cohort, although at the time
of sampling the study subjects were not receiving antibiotics.
On the other hand, the homogenous ethnic background of the study population could be
considered as a strength. Our cohort included children with varying ages and biopsy locations,
and both of these factors were included as confounders in the microbiota analysis. Similar to our
results, age has been found to have a significant impact on the composition of both mucosal and fecal
microbiota in children [18,23]. Concerning biopsy location, our results were not fully conclusive that
mucosal microbiota would significantly differ between different parts of the colon, but for prudence it
was included as a confounder. Some previous studies have concluded that mucosal microbiota differs
significantly between colon segments [4], whereas others have considered it to be fairly comparable [17].
Our results on the comparison of microbiota between patients having active and inactive UC and
control subjects reassert the previously described UC-associated dysbiosis that has been characterized
by the depletion of anaerobic commensals and increase in facultatively anaerobic taxa [10,18], while
bacterial diversity or richness may not be affected [4]. We found depletion of Bacteroidetes and several
family-level taxa in the colonic mucosa of pediatric UC patients, which has also been described for
pediatric CD [17]. Bacteroides species, albeit also being opportunistic pathogens, are considered as
health-promoting in the gut mucosa, as they are capable of reinforcing the epithelial barrier, exerting
anti-inflammatory actions by releasing polysaccharide A (PSA), sphingolipids and outer membrane
vesicles, and ameliorating experimental colitis [24–26].
We observed that UC patients had an increased amount of Enterobacteriaceae and other unclassified
Gammaproteobacteria, Sutterellaceae, Veillonellaceae, Streptococcaceae and Peptostreptococcaceae,
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which was emphasized in the patients with active disease. This replicates previous studies showing
these taxa to be increased in pediatric CD or UC [17,18], and particularly Gammaproteobacteria
and Enterobacteriaceae are renowned for their proinflammatory properties due to the production
of lipopolysaccharide (LPS) [9,10]. Veillonellaceae and specific species within Streptococcaceae
have also been previously linked with more severe disease progression in new-onset pediatric
UC [18]. Concerning Sutterellaceae, the association with IBD is unclear as the results vary between
studies [17,18,27]. All these families, excluding Peptostreptococcaceae, are aerotolerant and increased
oxygen levels in the inflamed gut may promote their growth, as suggested by the oxygen hypothesis [28].
Peptostreptococcaceae are anaerobic commensals, whose increased abundance in UC may be linked
to other factors than increased oxygen levels during inflammation, such as altered expression of
antimicrobial peptides in the epithelium, which is supported by the result that Peptostreptococcaceae
abundance correlated negatively with the expression of REG3G. The expansion of this bacterial taxa
has been previously observed in adult UC patients in remission [14].
A novel finding in our study was that patients with inactive UC had an increased abundance
of Saccharibacteria as compared to non-IBD and active UC patients, and that across all samples
Saccharibacteria correlated positively with Micrococcaceae and Ruminococcaceae, the latter of which
has been found to be reduced in treatment-naïve pediatric UC and CD [17,18]. Saccharibacteria (formerly
known as the TM7 phylum) are ultrasmall bacteria, which parasitize on other bacteria and display
highly dynamic interactions with their hosts, including virulent killing [29]. Thus, Saccharibacteria
may affect the gut microbiota structure and functionality, and consequently mucosal homeostasis.
For example, specific species of Saccharibacteria have been shown to silence the ability of its host
bacterium to induce TNF-alpha expression in macrophages [30]. Thereby, our finding on the increased
abundance of Saccharibacteria in inactive UC is of particular interest, and the possible involvement of
this bacterial group in fluctuating microbiota composition and remission–relapse cycling in UC should
be studied further.
Overall, it seems that the shifts in the balance of the mucosal microbiota in UC towards increased
proportions of pro-inflammatory bacteria, especially Enterobacteriaceae, and decreased proportions
of anti-inflammatory bacteria, such as Bacteroides spp., may initiate and exacerbate inflammation.
The origin of microbiota shifts is an intriguing question, and future studies should address microbiota
changes in patients longitudinally across remission–relapse cycles and also investigate the possible role
of less studied microbial groups in the shifts, including phages and the ultrasmall bacterial parasites
Saccharibacteria that were found to be increased in UC in this study.
The quantitative expression analysis of 13 selected genes revealed differential expression of six
genes in UC as compared to non-IBD. These included IL-8 and CXCL16, which were previously found
to have increased expression in pediatric UC patients [5], as well as the calcium binding proteins
S100A8 and S100A9, whose complex is also known as calprotectin—an established biomarker of disease
activity in UC and other chronic inflammatory diseases. We also confirmed now in a pediatric cohort
the previous findings of decreased expression of antimicrobial defensin β 1 (DEFB1), a key effector of
the innate immune system [31]. Moreover, we showed that the decrease in expression could be linked
to an increased Enterobacteriaceae abundance. Defective production of DEFB1 could potentially lead
to the increased levels of proinflammatory bacteria and, therefore, activation of the mucosal immune
system and activity of the inflammatory disease.
In addition to these findings, we showed that Sutterellaceae and Veillonellaceae had a positive
correlation with the expression of CXCL16 and although the causal link remains speculative, the
possible regulatory functions of these taxa on mucosal CXCL16 expression is an intriguing question
that could be addressed in future studies. Interestingly, the expression of CXCL16, S100A8 and S100A9
correlated negatively with Lactobacillaceae, which are proposed to exert anti-inflammatory action in
the gut [32]. However, we did not find correlation between the abundance of Lactobacillaceae and the
expression of the selected AMP, although recent animal model studies have shown that Lactobacillus
spp. could stimulate AMP production [33–35].
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The negative correlation between the expression of antimicrobial peptides REG3g and DEFB1 and
Peptostreptococcaceae and Enterobacteriaceae may partly explain the increase in abundance of these
taxa in UC. On the other hand, Betaproteobacteria abundance correlated negatively with the expression
of DEFB4A, and although DEFB4A expression did not differ between the study groups, the result
supports the idea that a repertoire of antimicrobial peptides participates in maintaining microbiota
eubiosis. However, the positive correlation between LCN2 expression and Enterobacteriaceae may
suggest that these bacteria induce the expression of the siderophore binding protein as a host defense
mechanism to limit the availability of iron and subsequently bacterial growth.
In summary, our results reinforce the suggestion that reciprocal interaction of mucosal microbiota
and epithelial defense mechanisms play a role in UC. The depletion of Bacteroidetes and increase in
facultative anaerobes including Enterobacteriaceae may negatively affect the immunological tolerance
towards gut microbiota. The negative correlation between the expression of antimicrobial peptides
and specific taxa suggests that impaired host defense mechanisms may allow the expansion of
specific microbes able to exacerbate inflammation in UC. The results provide leads for further studies
to investigate host–microbiota interactions and can help to develop strategies to restore mucosal
microbiota and homeostasis in UC.
4. Materials and Methods
4.1. Patients
Patients were recruited at the Department of Pediatrics in Turku University Hospital, Turku,
Finland and Tampere University Hospital, Tampere, Finland. Endoscopies were done on the clinical
basis due to a previous diagnosis of UC or symptoms suggestive of IBD. Endoscopic findings in
colonoscopy were classified according to the Mayo endoscopic subscore as normal or inactive disease
(score 0), mild (score 1), moderate (score 2) and severe disease (score 3) [36]. The division of the patients
to the active and inactive UC groups was based on the histological scoring, which was in accordance
with the endoscopic Mayo scoring. The following groups of patients were included in the study:
children with endoscopically active UC (n = 18), children with clinically and endoscopically quiescent
UC (n = 8) and 27 children with macroscopically and microscopically non-inflamed colon to whom
endoscopy was done due to various reasons (Table 1), such as chronic diarrhea (n = 7), abdominal
pain (n = 8), hematochezia (n = 9) or other gastrointestinal symptoms (n = 3). These were included
in the study as non-IBD controls. In children with active UC, biopsies were taken in the involved
area, i.e., where macroscopic inflammation was found during endoscopy, and these locations included
cecum and ascending and descending colon. In inactive UC and non-IBD subjects, biopsies were
collected from the same locations to allow reasonable comparison between the groups. The study
cohort demographics are presented in Table 1. The study subjects were not receiving antibiotics at the
time of sampling or for four weeks prior to the sampling. Written informed consent was obtained from
all the study patients or their parents. The study was accepted by the ethical committee of the hospital
district of Southwest Finland.
4.2. Isolation of Host RNA and Microbial DNA
Two biopsies, one for microbial DNA extraction and one for RNA isolation, were taken from
each patient, in addition to the routine biopsies for histological examination. The biopsy was taken in
the involved area if macroscopic inflammation was found during endoscopy. Otherwise, the biopsy
was taken in a non-involved area. In any case, a sample for histological evaluation was taken in the
same area as the biopsy for RNA isolation in order to confirm whether the area was inflamed or not.
The collected biopsies represented different locations, i.e., cecum, ascending and descending colon
(Table 1). Biopsy samples for microbial DNA isolation were frozen in −80 ◦C within 2 h of collection,
and the microbial DNA was extracted as described previously [37]. Biopsy samples for RNA analysis
were rinsed with RNAse-free water and then immediately immersed in RNAlater RNA stabilization
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reagent (Qiagen, Hilden, Germany), then incubated at 4 ◦C for 1 day and stored at −20 ◦C until RNA
isolation. After the tissue homogenization, isolation of RNA was performed by RNeasy Plus Mini-kit
(Qiagen) according to the manufacturer’s instructions [37]. Quality of the isolated RNA was analyzed
with Bio-Rad Experion System (Bio RAD Laboratories, Hercules, CA, USA).
4.3. 16.S rDNA Amplicon Sequencing
Amplicons from the V1 to V2 region of 16S rRNA genes were generated by PCR
using the degenerated primers 27F-DegL (5′-AGRGTTYGATYMTGGCTCAG-3′) and 338R
(5′-TGCTGCCTCCCGTAGGAGT-3′) producing a ~311 bp amplicon [38]. To facilitate pyrosequencing
using titanium chemistry, each forward primer was appended with the titanium sequencing adaptor A
and an “NNNNNNNN” barcode sequence at the 5′ end, where NNNNNNNN is a sequence of eight
nucleotides that was unique for each sample. The reverse primer carried the titanium adaptor B at the
5′ end.
PCRs were performed using a Mx3005P thermocycler (Stratagene, La Jolla, CA, USA) in a total
volume of 25 µL containing 1× PCR buffer, 1 µL PCR-grade nucleotide mix, 2.4 units of AmpliTaq Gold
DNA polymerase (Applied Biosystems/Life Technologies Waltham, MA, USA), 200 nM forward and
reverse primers (Oligomer, Helsinki, Finland) and 100 to 300 ng of template DNA. The amplification
program consisted of an initial denaturation step at 96 ◦C for 2 min; 35 cycles of denaturation at 96 ◦C
for 30 s, annealing at 56 ◦C for 45 s and elongation at 72 ◦C for 60 s; and a final extension step at 72 ◦C for
10 min. Three parallel reactions per sample were prepared. The size of the PCR products was confirmed
by gel electrophoresis using 1% (wt/vol) agarose gel and ethidium bromide staining. Control PCRs
were performed alongside each separate amplification without addition of template, and consistently
yielded no product. PCR products from 3 to 5 parallel reactions were pooled and purified with the
QIAquick PCR purification kit (Qiagen, Hilden, Germany) followed by DNA yield quantification
using a NanoDrop ND-1000 spectrophotometer. The pooled amplicons were pyrosequenced using a
454-GS FLX titanium chemistry (Roche Diagnostics, Rotkreuz, Switzerland) in the sequencing core
facility in the Institute of Biotechnology, University of Helsinki using the manufacturer´s protocols.
Data published in ENA ref. no PRJEB38527.
4.4. qRT-PCR of Mucosal Gene Expression
Reverse transcription reactions were done by High Capacity cDNA reverse transcription kit
(Applied Biosystems/Life Technologies Corporation, Carlsbad, CA, USA) as described previously [5,37].
Gene expression assays were performed according to the protocol using the comparative Ct (threshold
cycle)-method with Applied Biosystems´ ABI 7300 Real Time PCR System and targeting the
genes of interest based on previous literature. The following 14 genes were analyzed (Taqman
Gene Expression Assay ID in brackets): IL8 (Hs00174103_m1), CXCL16 (Hs00222859_m1), CXCR6
(Hs01890898_s1), DEFB1 (Hs00608345_m1), DEFB103B (Hs04194486_g1), DEFB4A (Hs00823638_m1),
LCN2 (Hs01008571_m1), MUC2 (Hs03005103_g1), REGIIIg (Hs01595406_g1), RETNLB (Hs00395669_m1),
S100A8 (Hs00374263_m1), S100A9 (Hs00610058_m1), TFF3 (Hs00902278_m1) and 18S rRNA
(Hs99999901_s1). The expression of the 18S rRNA gene was used as an endogenous control due to its
constant expression in all the study samples [5]. Thermal cycler conditions were (1) 50 ◦C for 2 min,
(2) 95 ◦C for 10 min, (3) 95 ◦C for 15 s and (4) 60 ◦C for 1 min, with 40 cycles of steps 3 and 4. Negative
and positive (cDNA of the Universe Human Reference RNA, Agilent Technologies, Santa Clara, CA,
USA) controls were included in all PCR runs. Results were analyzed with Applied Biosystems´
RQ-Study program and gene expressions relative to the positive control were calculated as previously
described [5,37].
4.5. 16.S rDNA Amplicon Data Analysis
Pyrosequences were sorted per barcode. We processed 876,571 raw reads using in-house R
scripts and the Quantitative Insights Into Microbial Ecology (QIIME) software package version 1.9 [39].
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Preprocessing in R included removal of chimeric reads by mapping to the ChimeraSlayer reference
database (Broad MIcrobiome Utilities version microbiomeutil-r20110519) using the Usearch v. 8.0.1623
uchime_ref algorithm with default settings [40,41]. Furthermore, sequences having length <300 nt
were excluded. In QIIME, the preprocessing included removing reads lacking a barcode or primer
sequence and removing the forward and reverse primer sequences from the reads. The quality control
steps in QIIME were done with default settings. Briefly, a maximum of 6 ambiguous bases per read was
allowed and sequences were discarded if the average quality score over a sliding window spanning
50 nucleotides dropped below 25 [39]. The final dataset included 393,237 reads, with a mean read
count of 5869 per sample. The OTUs detected once across all samples were removed. OTUs for the
filtered reads were defined at 97% sequence similarity using UCLUST in QIIME [40]. Representative
sequences from each OTU were taxonomically assigned with the Uclust method and the SILVA v.119
reference database in QIIME.
4.6. Statistical Analysis
The data analysis was performed in R version 2.15.1 (R Development CT 2012) and by using
in-house scripts. Microbial richness and the community diversity (Shannon diversity) and the
proportion of how different parameters effect the variation (MANOVA) was calculated using functions
from the Vegan package. Microbiota compositional analysis was conducted using MARE functions
using the family taxonomical level [42]. Principal co-ordinate analysis (PCoA) was used to visualize
the dissimilarities in the microbial community using Bray–Curtis dissimilarities.
The statistical difference in family-level taxa abundances between UC and non-IBD as well as
UC active and inactive and non-IBD was tested with generalized linear mixed models with functions
from the MARE R package. The read number for each sample was used as an offset to account for
the varying sequencing depth and biopsy location, and sequencing patch and subjects’ age were used
as confounding factors. The obtained p-values were corrected using multiple testing with the false
discovery rate approach. The values with p-values below 0.01 and FDR-adjusted p-values (q-values)
below 0.2 were considered to be significant. Associations between gene expression and bacterial
abundances were estimated with generalized linear mixed models with functions from the MARE R
package. The read number for each sample was used as an offset and the biopsy location and subjects’
age were used as confounding factors. The FDR-corrected p-values below 0.05 were considered to
be significant.
The difference in phylum-level abundances and gene expression levels between groups were
analyzed with ANOVA with Benjamini–Hochberg (BH) adjustment. The correlations between bacterial
groups and gene expressions were estimated by Spearman coefficient, followed by FDR correction
(BH) of p-value.
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